Chennai, India; May 13, 2020:
Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced the launch of a Single Inhaler Triple Therapy AIRZ-FF – a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD).
This new triple therapy innovation comes with multiple benefits: it offers significant bronchodilation (making breathing easier), reduces risk of severe attacks, and eliminates dependence on multiple inhalers. The reduction in risk of severe attacks decreases the requirement for hospitalization, a benefit of high significance in current prevailing situation.
AIRZ-FF has been exclusively studied in the Indian population and introduced to address challenges faced by a significant portion of COPD patients in the country. COPD is a very common, serious and debilitating lung disease which like hypertension or diabetes, requires personalized treatment over the rest of the patient’s life.
India is currently home to more than 55.3 million people living with COPD of varying degrees of severity. The disease prevalence has grown significantly by 24% in the last decade alone. Health experts attribute this rise to low levels of awareness and low rates of diagnosis of the disease. Together these factors have made COPD the second leading cause of death by disease in India.
According to global organizations on respiratory medicine, patients most likely to benefit from triple therapy, include those with history of multiple or severe attacks, despite appropriate use of singular or dual bronchodilators alone.